Go ahead, I'm gonna keep writing my stock picks and market direction calls right here though. Just start a new thread and I won't bother ya.
Among the many other impacts that the Silicon Valley Bank (NASDAQ:SIVB) collapse had, huge number of customers have applied to shift their accounts to large U.S. banks such as JPMorgan Chase (NYSE:JPM) and Citigroup (NYSE:C) from smaller lenders. Financial Times reports that these lenders include Bank of America (NYSE:BAC) which is trying to accommodate such transfer requests by taking extra steps to speed up the normal sign-up process, among other steps. Despite U.S. government's emergency measures to stop the collapse of more banks, depositors continue to look to larger banks or to shift to money market funds. The Federal Deposit Insurance Corporation last week agreed to protect the deposits of up to $250K but deposits above that amount (accounting for 85% of SVB accounts) are at a risk. In premarket trade, JPM, C and BAC are up 1.7%, 2.6% and 3.4% respectively.
I really wish you wouldn't. This thread is mine and when I close it I would appreciate you not messing around. I don't want to look back again. And I will not get any of your ideas that way.
MacroGenics expands license agreement with Synaffix Mar. 14, 2023 8:34 AM ET MacroGenics, Inc. (MGNX) Synaffix hasannouncedthe expansion of its license agreement with MacroGenics (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The expansion comes just a year after the original Feb. 2022 deal, increasingthe total potential consideration by up to $2.2B, plus tiered low to high single-digit royalties on potential net sales of any resulting products. Under the original licensing agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads. "The expansion of our agreement with MacroGenics is a significant milestone for Synaffix that further underscores the growing momentum behind our proprietary ADC technology." said Anthony DeBoer, VP of Business Development at Synaffix.
TrueCar (NASDAQ:TRUE) shares marked a double-digit gain in premarket trading on Tuesday as Needham Securities shifted to a bullish outlook. Equity analyst Chris Pierce moved from Hold to Buy on the stock, noting that normalization in the auto sales industry should help drive upside. “TRUE's combination of leverage to new vehicle sales as the industry slowly returns to normal and changes to TRUE's business model help US get comfortable playing offense, while TRUE's cash balance and further potential interest from strategic industry partners adds comfort on the defensive side,” Piece wrote. He set a $3.50 price target on the stock alongside the upgrade to Buy. Shares of TrueCar (TRUE) ticked9%higher prior to the bell on Tuesday.
Volkswagen (OTCPK:VWAGY) posted full-year results on Tuesday and outlined ambitious targets in EV and technology spending for coming years. For the full-year 2022, the German automaker posted an 11.6% jump in revenue from the prior year to €279.23B. Overall delivery numbers declined 7% from 2021, but operating margins grew 8.1% due to pricing actions. “We made headway on executing our strategy, despite extreme headwinds. BEVs accounted for a record 7 percent share of total deliveries – a significant milestone that we will build upon this year as our popular model range continues to grow,” CEO Oliver Blume said. “ We continued to strengthen our global presence by concentrating the production and development of our excellent products and technologies even more locally in the markets. FY23 will be a decisive year for executing strategic goals and accelerating progress across the group.” Management touted a “high order book of 1.8M vehicles and a unique product portfolio” heading into 2023. Supply chain issues are also expected to ease into 2023, allowing for delivery growth into the year. However, most striking in the company’s guidance is the plan to invest In total, the Group is planning to invest €180B ($192.9M) between 2023 – 2027 in “the most attractive profit pools and regions, with more than two-thirds allotted for electrification and digitalization.” The investments will be directed toward battery plants, growth in both North America and CHina, and continued digitalization of vehicles. “We aim to again generate robust returns in the current year,” CFO Arno Antlitz concluded. “Our strong financial basis puts us in a position to continue investing in the electrification and digitalization of our company, even in a challenging economic environment.”
AMLX Stock: Inventory Build-Up Is Key There were about 1,300 patients on Relyvrio at the end of the fourth quarter. "Company expects to double that in the first quarter," Some $7 million of the fourth-quarter sales are due to two weeks of inventory build-up, he noted. This suggests the ALS treatment could pull in $3.5 million a week. That puts Relyvrio at a run rate of $42 million for the first quarter. But analysts expect Relyvrio to top that at $60 million. Approval In Europe, Additional Testing SVB Securities analyst Marc Goodman says a third of commercial policies in the U.S. now reimburse for Relyvrio. The drug also is approved in Canada under the brand name Albrioza, and Amylyx expects a regulatory decision in Europe by midyear with an approval decision in the third quarter. Meanwhile, Amylyx is still running final-phase testing of the ALS treatment to examine whether it has a benefit on patients' survival long term. Goodman expects that final survival data won't be available until 2025, at the earliest. That gives Relyvrio a strong commercial start while those results are pending.
It's kinda "our" thread ya know. I mean really. You'll be coming back anyway when a stock you highlighted takes off, but whatever. Sooo... start a new thread, I'll do whatever you want Stoney, you're as much a part of my morning routine as is that nasty coffee yulia buys.
fairly confident this has based out at a low. ( I hope)// Adding GSAT Time To Buy- Globalstar, Inc. (GSAT)-$1.15 NYSE American - Nasdaq Real Time Price. 1.15 00+0.0200 (+1.7699%) As of 10:04AM EDT.